Scarica l'app Stockscreener
2.45
6.84%
-0.18
Dopo l'orario di chiusura:
2.53
0.08
+3.27%
Precedente Chiudi:
$2.63
Aprire:
$2.58
Volume 24 ore:
62,904
Relative Volume:
0.72
Capitalizzazione di mercato:
$2.96M
Reddito:
$4.96M
Utile/perdita netta:
$-6.82M
Rapporto P/E:
-0.0375
EPS:
-65.4
Flusso di cassa netto:
$-6.64M
1 W Prestazione:
-10.91%
1M Prestazione:
-16.87%
6M Prestazione:
-42.89%
1 anno Prestazione:
-56.25%
Intervallo 1D:
$2.34
$2.90
Intervallo di 1 settimana:
$2.34
$2.93
Portata 52W:
$1.72
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Nome
Inmed Pharmaceuticals Inc
Settore
Telefono
(604) 669-7207
Indirizzo
1445-885 WEST GEORGIA ST., VANCOUVER
Confronta INM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
2.45 | 3.32M | 4.96M | -6.82M | -6.64M | -65.40 |
|
HLN
Haleon Plc Adr
|
11.33 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
167.14 | 72.11B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.76 | 4.24M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 45.01B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.53 | 19.43B | 16.54B | -1.64B | 749.00M | -1.45 |
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
InMed Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022 - Seeking Alpha
InMed Pharmaceuticals (NASDAQ:INM) Trading Down 11.5% – Here’s What Happened - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
InMed Pharmaceuticals Advances Drug Pipeline Amid Financial Challenges - TipRanks
InMed Reports Third Quarter Fiscal 2025 Financial Results and Pr - GuruFocus
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
SEC Form PRE 14A filed by InMed Pharmaceuticals Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
InMed Pharmaceuticals cancels special shareholder meeting By Investing.com - Investing.com Canada
InMed Pharmaceuticals cancels special shareholder meeting - Investing.com
InMed Pharmaceuticals sets date for special shareholder meeting By Investing.com - Investing.com South Africa
InMed Pharmaceuticals sets date for special shareholder meeting - Investing.com
InMed Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com Australia
InMed Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com South Africa
InMed Pharmaceuticals : Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview - MarketScreener
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 By Investing.com - Investing.com India
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 - Investing.com India
InMed Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.79%
3.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):